H.I.G. BioVentures invests in a broad range of life science opportunities across sectors and stages. Our seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. We invest in companies developing novel products for significant unmet medical needs, primarily in the following sectors:

• Therapeutics (small molecules, protein therapeutics, antibodies, etc.)
• Medical devices
• Diagnostics

After making an investment, the H.I.G. BioVentures team works closely with portfolio companies in key areas, including:

• Pre-clinical and clinical development strategy
• Management recruitment
• Business development activities
• Follow on equity and debt financing
• Achieving liquidity through M&A or IPO

"Tranzyme Pharma was in a preclinical stage when we approached H.I.G. BioVentures for funding. Not many investors would consider companies at such and early stage, but H.I.G. BioVentures understood the market and the need for innovative products that treat gastrointestinal and metabolic diseases and took the risk. One year after the financing, we have successfully completed a Phase I trial of our lead product and anticipate having a second candidate in the clinic by 2007."

- Vipin K. Garg, Ph.D., President and CEO, Tranzyme Pharma